Consensus Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Real-time Estimate Cboe BZX 11:28:02 2024-04-26 am EDT 5-day change 1st Jan Change
4.05 USD -0.74% Intraday chart for Autolus Therapeutics plc -10.07% -36.88%

Evolution of the average Target Price on Autolus Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

2e2a7d1470c79ef8d10b7.tPihwbEuOl-1Hlis3fb_A63rYx0gsDAcAPZQFmaLd6o.5JvCl8IeQwqESQf4iaytRp6zD3xhygIvcrpnIyzaRpyZufeUhUVTGMxtYA~c0921b45b182ab6086460487910574d8
Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating MT
Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating MT
Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating MT
Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating MT
Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target MT
Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating MT
Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating MT
Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target MT
Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating MT
Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating MT
Syncona portfolio firm hits 70% remission rate goal in leukaemia trial AN
European Equities Follow US Markets Lower on Interest Rate Concerns MT
Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating MT
Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating MT
HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating MT
AUTOLUS THERAPEUTICS : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating MT
AUTOLUS THERAPEUTICS : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6 MT
AUTOLUS THERAPEUTICS : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating MT
AUTOLUS THERAPEUTICS : Redburn Downgrades Autolus Therapeutics to Neutral from Buy MT
AUTOLUS THERAPEUTICS : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24 MT
AUTOLUS THERAPEUTICS : HC Wainwright Adjusts Autolus Therapeutics' Price Target to $13 From $19, Keeps at Buy MT
AUTOLUS THERAPEUTICS : HC Wainwright Analyst Starts Autolus Therapeutics at Buy With $19 Price Target MT
AUTOLUS THERAPEUTICS : Redburn Initiates Coverage on Autolus Therapeutics With Buy Rating MT
Berenberg US Conference FA
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.08 USD
Average target price
10.54 USD
Spread / Average Target
+158.44%
High Price Target
16 USD
Spread / Highest target
+292.16%
Low Price Target
6.9 USD
Spread / Lowest Target
+69.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Autolus Therapeutics plc

Truist Securities
Needham & Co.
Goldman Sachs
Deutsche Bank Securities
Wells Fargo Securities
Mizuho Securities
HC Wainwright
Jefferies & Co.
Redburn
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. Consensus Autolus Therapeutics plc